Survival following Multimodality Treatment Including Surgery for Stage IA–IIIB Small-Cell Lung Cancer

Weckler, Barbara; Baldes, Natalie; Schirren, J.

doi:10.1055/s-0038-1667145

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single-center study by Weckler, B. C. et al retrospectively enrolled 47 patients of SCLC with stage IA-IIIB who underwent combined treatment including surgery (including 6 stage T4 patients), resulting in a postoperative 30-day mortality rate of 0% and good long-term survival with a median overall survival of 56 months. His study evaluated that R0 resection was the only factor influencing long-term survival [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

An extensive surgical resection in stage T4 small cell lung cancer with cardiac invasion: A case report and literature review

Xiong

Tang

Luo

2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

An extensive surgical resection in stage T4 small cell lung cancer with cardiac invasion: A case report and literature review

Xiong

Tang

Luo

2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…In some studies, lobe resection was reported to be associated with a longer OS than other types of surgery ( 34 , 35 ). Zhang et al indicated that the combined components of NSCLC would affect the OS ( 12 ), while Weckler BC suggests that complete resection was the only predictor of OS ( 36 ). However, in patients with NSCLC, nerve invasion or vascular invasion have also influenced the OS ( 37 , 38 ).…”

Section: Discussionmentioning

confidence: 99%

Using T stage and tumor thrombosis as predictive factors for patients with resected I–IIA small cell lung cancer: a retrospective study

Mao¹,

Ni²,

Niu³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Surgery is recognized as an important part of treating stage I-IIA small cell lung cancer (SCLC), but few studies have explored the predictive factors for overall survival (OS) or time to tumor progression (TTP). This paper aims to explore the predictive factors related to improved overall and relapse-free survival. Methods: Patients with stage I-IIA SCLC were reviewed between January 1st, 2014, and December 30th, 2016, at the Shanghai Chest Hospital. Basic patient characteristics and clinical data were collected, including age, sex, tumor (T) stage, pathological characteristics, and treatment. Patient follow-ups were conducted by checking medical records or phoning the patient, with survival data and instances of recurrence and/ or metastasis being collected and recorded. Univariate and multivariate analyses were used to identify the predictive factors.Results: A total of 59 patients were enrolled in this study, and the median follow-up duration was 53.7 months. The 3-year disease free and 3-year OS rates were 62.5% and 75.0%, respectively. The 5-year disease free and 5-year OS rates were not reached. Univariate and multivariate analyses revealed that a higher T stage [hazard ratio (HR) 3.210, P=0.048], the presence of tumor thrombosis (HR 6.021, P=0.043), and the absence of adjuvant chemotherapy (HR 3.425, P=0.059) were more reflective of shorter TTP than other factors, with the presence of adjuvant chemotherapy also correlating with improved OS. Conclusions:A patient having a T1 stage with no tumor thrombus and receiving adjuvant chemotherapy were observed as positive factors for longer periods of TTP, and adjuvant chemotherapy was a favorable predictor for the OS of patients with resected stage I-IIA SCLC.

show abstract

“…Systemic therapy, including chemotherapy, radiotherapy, and immunotherapy, has been widely accepted for the treatment of SCLC. Although the current National Comprehensive Cancer Network (NCCN) guidelines only recommend surgery for patients with clinical stages I-IIA SCLC (6), many studies have also found that patients with clinical stages II-III SCLC can also benefit from surgery (7)(8)(9)(10)(11)(12)(13). In addition, although more advanced diagnostic methods are now used for the diagnosis and classification of SCLC, the selection of surgical candidates for SCLC is still arbitrary.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors of patients with small cell lung cancer after surgical treatment

Zeng¹,

Li²,

Li³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: The current National Comprehensive Cancer Network guidelines recommend surgical treatment for patients with stages I-IIA small cell lung cancer (SCLC), but it still cannot deny the effect of surgical treatment on other limited-stage SCLC. Although more advanced diagnostic methods are now used for the diagnosis and classification of SCLC, the selection of surgical candidates is still arbitrary.Methods: Data were collected from patients with SCLC who underwent surgery at the First Affiliated Hospital of Zhengzhou University from January 2011 to January 2021. Kaplan-Meier method was used to calculate cumulative survival curves, and log-rank test was used to evaluate differences among different subgroups. The Cox proportional hazard regression model was used to assess the predictive power of the variables for prognosis and survival. Results: Smoking index, surgical resection method, TNM stage of postoperative pathology, and postoperative chemotherapy were significantly correlated with postoperative survival (P<0.05), which were independent predictors for postoperative survival. Patients with a smoking index >800 had a higher risk of death after surgery [hazard ratio (HR): 7.050, 95% confidence interval (CI): 3.079-16.143, P<0.001]. Compared with patients who underwent pulmonary lobectomy, those who underwent other pneumoresections (e.g., wedge resection, segmental resection, sleeve resection) had an increased risk of death (HR: 2.822, 95% CI: 1.030-7.734, P=0.044). Compared with stage I patients, stage II and stage III patients had an increased risk of death, with HRs of 6.039 and 3.145, respectively. Compared with those who received ≤4 courses of postoperative chemotherapy, those who received >4 courses of postoperative chemotherapy had reduced postoperative mortality risk (HR: 0.211, 95% CI: 0.097-0.459, P<0.001). Conclusions: A high smoking index suggests worse prognosis; therefore, patients who smoke should be advised to quit smoking. Compared with stage II and stage III patients, surgical treatment is recommended for stage I SCLC patients. TNM staging, especially N staging, should be evaluated prior to surgery. Pulmonary lobectomy with mediastinal lymph node dissection should be the preferred surgical treatment for patients with SCLC. Patients should receive at least 5 courses of adjuvant chemotherapy after surgery.

show abstract

Survival following Multimodality Treatment Including Surgery for Stage IA–IIIB Small-Cell Lung Cancer

Cited by 9 publications

References 20 publications

An extensive surgical resection in stage T4 small cell lung cancer with cardiac invasion: A case report and literature review

An extensive surgical resection in stage T4 small cell lung cancer with cardiac invasion: A case report and literature review

Using T stage and tumor thrombosis as predictive factors for patients with resected I–IIA small cell lung cancer: a retrospective study

Prognostic factors of patients with small cell lung cancer after surgical treatment

Contact Info

Product

Resources

About